{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:29:19Z","timestamp":1790130559269,"version":"4.0.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Opinion Statement<\/jats:title>\n                  <jats:p>Plasminogen activator inhibitor-1 (PAI-1) plays a multifaceted and central role in the tumor biology of various skin malignancies. Beyond its classical function in fibrinolysis, PAI-1 contributes to tumor progression by promoting immunosuppression, angiogenesis, cellular senescence, and tissue remodeling. Its expression is particularly elevated in aggressive disease stages across cutaneous melanoma, cutaneous squamous cell carcinoma (cSCC), cutaneous angiosarcoma (CAS), and mycosis fungoides (MF), and is associated with poor clinical outcomes. The ability of PAI-1 to induce senescence-associated secretory phenotype (SASP), modulate PD-L1 expression, and recruit tumor-associated macrophages (TAMs) and cancer-associated fibroblasts (CAFs) suggests a key role in shaping the immunosuppressive tumor microenvironment (TME). This positions PAI-1 as both a potential biomarker for disease progression and a therapeutic target for restoring immune responsiveness, especially in tumors resistant to immune checkpoint inhibitors (ICIs). The PAI-1 inhibitor TM5614 has demonstrated promising activity in early clinical studies, particularly in anti-PD-1-refractory melanoma, and is currently under evaluation in multiple Phase II and III trials. Future strategies should focus on patient stratification using biomarkers such as SASP factors and PAI-1 levels, as well as rational combination therapies targeting interconnected pathways like IL-17\/IL-23, AhR, and senescence signaling. Overall, PAI-1 inhibition offers a novel and mechanistically grounded approach to improve outcomes in skin cancers characterized by therapy resistance and an immunosuppressive microenvironment.<\/jats:p>","DOI":"10.1007\/s11864-025-01357-x","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T10:49:47Z","timestamp":1758883787000},"page":"943-949","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["PAI-1 in Skin Malignancies: a Central Regulator of Tumor Progression and Therapeutic Resistance"],"prefix":"10.1007","volume":"26","author":[{"given":"Taku","family":"Fujimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihide","family":"Asano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"issue":"15","key":"1357_CR1","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-15-0876","volume":"75","author":"VR Placencio","year":"2015","unstructured":"Placencio VR, DeClerck YA. Plasminogen activator inhibitor-1 in cancer: rationale and insight for future therapeutic testing. Cancer Res. 2015;75(15):2969\u201374.","journal-title":"Cancer Res"},{"issue":"3","key":"1357_CR2","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/j.1365-2141.2012.09074.x","volume":"157","author":"T Iwaki","year":"2012","unstructured":"Iwaki T, Urano T, Umemura K. PAI-1, progress in understanding the clinical problem and its aetiology. Br J Haematol. 2012;157(3):291\u20138.","journal-title":"Br J Haematol"},{"key":"1357_CR3","doi-asserted-by":"publisher","first-page":"798385","DOI":"10.3389\/fonc.2021.798385","volume":"11","author":"K Ohuchi","year":"2021","unstructured":"Ohuchi K, et al. Plasminogen activating inhibitor-1 might be a predictive marker for the efficacy of anti-PD1 antibody in advanced melanoma patients. Front Oncol. 2021;11:798385.","journal-title":"Front Oncol"},{"key":"1357_CR4","doi-asserted-by":"publisher","unstructured":"Miyata T. Overview: PAI-1 inhibitors and clinical applications. Biomed J. 2025, in press. https:\/\/doi.org\/10.1016\/j.bj.2025.100874.","DOI":"10.1016\/j.bj.2025.100874"},{"issue":"1","key":"1357_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01910-5","volume":"22","author":"SB Shaikh","year":"2024","unstructured":"Shaikh SB, et al. A signaling pathway map of plasminogen activator inhibitor-1 (PAI-1\/SERPINE-1): a review of an innovative frontier in molecular aging and cellular senescence. Cell Commun Signal. 2024;22(1):544.","journal-title":"Cell Commun Signal"},{"key":"1357_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2025.102694","volume":"106","author":"A Salminen","year":"2025","unstructured":"Salminen A. Cooperation between inhibitory immune checkpoints of senescent cells with immunosuppressive network to promote immunosenescence and the aging process. Ageing Res Rev. 2025;106:102694.","journal-title":"Ageing Res Rev"},{"issue":"7","key":"1357_CR7","doi-asserted-by":"publisher","first-page":"4044","DOI":"10.3390\/ijms23074044","volume":"23","author":"T Fujimura","year":"2022","unstructured":"Fujimura T. Significance of stromal factors as a target for immunotherapy in melanoma and non-melanoma skin cancers. Int J Mol Sci. 2022;23(7):4044.","journal-title":"Int J Mol Sci"},{"key":"1357_CR8","doi-asserted-by":"crossref","unstructured":"Fujimura T. Significance of PAI-1 on the development of skin cancer: optimal targets for cancer therapies. Biomed J. 2025, in press.","DOI":"10.1016\/j.bj.2025.100850"},{"issue":"4","key":"1357_CR9","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/j.bbrc.2014.07.070","volume":"450","author":"B Thapa","year":"2014","unstructured":"Thapa B, et al. Plasminogen activator inhibitor-1 regulates infiltration of macrophages into melanoma via phosphorylation of FAK-Tyr925. Biochem Biophys Res Commun. 2014;450(4):1696\u2013701.","journal-title":"Biochem Biophys Res Commun"},{"issue":"11","key":"1357_CR10","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1016\/j.jid.2021.03.030","volume":"141","author":"YJ Tseng","year":"2021","unstructured":"Tseng YJ, et al. Inhibition of PAI-1 blocks PD-L1 endocytosis and improves the response of melanoma cells to immune checkpoint Blockade. J Invest Dermatol. 2021;141(11):2690\u20138.","journal-title":"J Invest Dermatol"},{"key":"1357_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1365894","volume":"15","author":"A Ibrahim","year":"2024","unstructured":"Ibrahim A, et al. Plasminogen activator inhibitor-1 promotes immune evasion in tumors by facilitating the expression of programmed cell death-ligand 1. Front Immunol. 2024;15:1365894.","journal-title":"Front Immunol"},{"issue":"41","key":"1357_CR12","doi-asserted-by":"publisher","first-page":"6986","DOI":"10.1038\/sj.onc.1207859","volume":"23","author":"K Bajou","year":"2004","unstructured":"Bajou K, et al. Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene. 2004;23(41):6986\u201390.","journal-title":"Oncogene"},{"issue":"6","key":"1357_CR13","doi-asserted-by":"publisher","first-page":"e70024","DOI":"10.1111\/acel.70024","volume":"24","author":"J Giroud","year":"2025","unstructured":"Giroud J, et al. Targeting ATF6alpha attenuates UVB-Induced senescence and improves skin homeostasis by regulating IL8 expression. Aging Cell. 2025;24(6):e70024.","journal-title":"Aging Cell"},{"issue":"1","key":"1357_CR14","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41420-025-02377-0","volume":"11","author":"J Wu","year":"2025","unstructured":"Wu J, et al. Endothelial senescence induced by PAI-1 promotes endometrial fibrosis. Cell Death Discov. 2025;11(1):89.","journal-title":"Cell Death Discov"},{"issue":"1","key":"1357_CR15","doi-asserted-by":"publisher","first-page":"16321","DOI":"10.1038\/s41598-024-66624-7","volume":"14","author":"P Bogdanowicz","year":"2024","unstructured":"Bogdanowicz P, et al. Senomorphic activity of a combination of niacinamide and hyaluronic acid: correlation with clinical improvement of skin aging. Sci Rep. 2024;14(1):16321.","journal-title":"Sci Rep"},{"issue":"2","key":"1357_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17020324","volume":"17","author":"T Ikawa","year":"2025","unstructured":"Ikawa T, et al. Impact of hyaluronic acid on the cutaneous T-cell lymphoma microenvironment: a novel anti-tumor mechanism of bexarotene. Cancers (Basel). 2025;17(2):324.","journal-title":"Cancers (Basel)"},{"key":"1357_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.120591","volume":"301","author":"BW Zheng","year":"2022","unstructured":"Zheng BW, et al. Different molecular weight hyaluronic acid alleviates inflammation response in DNFB-induced mice atopic dermatitis and LPS-induced RAW 264.7 cells. Life Sci. 2022;301:120591.","journal-title":"Life Sci"},{"issue":"1","key":"1357_CR18","doi-asserted-by":"publisher","first-page":"e3244","DOI":"10.1002\/hon.3244","volume":"42","author":"T Fujimura","year":"2024","unstructured":"Fujimura T, et al. Plasminogen activator inhibitor-1 promote angiogenesis through matrix metalloproteinase 9 in advanced mycosis fungoides. Hematol Oncol. 2024;42(1):e3244.","journal-title":"Hematol Oncol"},{"issue":"1","key":"1357_CR19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12974-019-1432-5","volume":"16","author":"Y Zuo","year":"2019","unstructured":"Zuo Y, et al. Activation of retinoid X receptor by bexarotene attenuates neuroinflammation via PPARgamma\/SIRT6\/FoxO3a pathway after subarachnoid hemorrhage in rats. J Neuroinflammation. 2019;16(1):47.","journal-title":"J Neuroinflammation"},{"issue":"5","key":"1357_CR20","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1093\/bjd\/ljae231","volume":"191","author":"T Fujimura","year":"2024","unstructured":"Fujimura T, et al. A phase II multicentre study of plasminogen activator inhibitor-1 inhibitor (TM5614) plus nivolumab for treating anti-programmed cell death 1 antibody-refractory malignant melanoma: TM5614-MM trial. Br J Dermatol. 2024;191(5):691\u20137.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1357_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14976","volume":"33","author":"T Fujimura","year":"2024","unstructured":"Fujimura T, et al. Efficacy and safety of TM5614 in combination with paclitaxel in the treatment of paclitaxel-resistant cutaneous angiosarcoma: phase II study protocol. Exp Dermatol. 2024;33(1):e14976.","journal-title":"Exp Dermatol"},{"issue":"4","key":"1357_CR22","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1002\/cam4.5292","volume":"12","author":"N Takahashi","year":"2023","unstructured":"Takahashi N, et al. Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor-1 inhibitor TM5614 combined with a tyrosine kinase inhibitor. Cancer Med. 2023;12(4):4250\u20138.","journal-title":"Cancer Med"},{"issue":"5","key":"1357_CR23","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.21037\/jtd-23-1858","volume":"16","author":"T Masuda","year":"2024","unstructured":"Masuda T, et al. Treatment rationale and protocol design: an investigator-initiated phase II study of combination treatment of nivolumab and TM5614, a PAI-1 inhibitor for previously treated patients with non-small cell lung cancer. J Thorac Dis. 2024;16(5):3381\u20138.","journal-title":"J Thorac Dis"},{"issue":"5","key":"1357_CR24","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.ccell.2025.02.024","volume":"43","author":"YP Zhang","year":"2025","unstructured":"Zhang YP, et al. PAI-1-driven SFRP2(high) cancer-associated fibroblasts hijack the abscopal effect of radioimmunotherapy. Cancer Cell. 2025;43(5):856\u201374.","journal-title":"Cancer Cell"},{"issue":"6","key":"1357_CR25","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/S1470-2045(21)00097-8","volume":"22","author":"I Pires da Silva","year":"2021","unstructured":"Pires da Silva I, et al. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. Lancet Oncol. 2021;22(6):836\u201347.","journal-title":"Lancet Oncol"},{"issue":"9","key":"1357_CR26","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1038\/s41591-023-02498-y","volume":"29","author":"A VanderWalde","year":"2023","unstructured":"VanderWalde A, et al. Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial. Nat Med. 2023;29(9):2278\u201385.","journal-title":"Nat Med"},{"issue":"4","key":"1357_CR27","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/1346-8138.16669","volume":"50","author":"A Takahashi","year":"2023","unstructured":"Takahashi A, et al. Updated analysis of nivolumab and ipilimumab combination therapy in Japanese patients with advanced melanoma. J Dermatol. 2023;50(4):525\u201335.","journal-title":"J Dermatol"},{"issue":"18","key":"1357_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13185560","volume":"13","author":"S Okuda-Hiwatashi","year":"2024","unstructured":"Okuda-Hiwatashi S, et al. The evaluation of immune checkpoint inhibitors and BRAF\/MEK inhibitors in different therapy lines for metastatic melanoma: a retrospective study. J Clin Med. 2024;13(18):5560.","journal-title":"J Clin Med"},{"issue":"1","key":"1357_CR29","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/bjd\/ljae343","volume":"192","author":"E Yamazaki","year":"2024","unstructured":"Yamazaki E, et al. Decreased serum levels of IL-4 correlate with the efficacy of the PAI-1 inhibitor TM5614 in patients with malignant melanoma refractory to anti-PD-1 antibodies: post hoc study of TM5614-MM trial. Br J Dermatol. 2024;192(1):167\u20139.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1357_CR30","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.cell.2020.07.038","volume":"182","author":"A Sadik","year":"2020","unstructured":"Sadik A, et al. IL4I1 is a metabolic immune checkpoint that activates the AHR and promotes tumor progression. Cell. 2020;182(5):1252\u201370.","journal-title":"Cell"},{"key":"1357_CR31","doi-asserted-by":"crossref","unstructured":"Dong L et al. Tolerogenic Monocyte-Derived Langerhans Cells Promote Melanoma Progression and Immunotherapy Resistance through Aryl Hydrocarbon Receptor-Cyclooxygenase-2 Activation. J Invest Dermatol. 2025, in press.","DOI":"10.1016\/j.jid.2025.02.155"},{"issue":"6801","key":"1357_CR32","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/35025220","volume":"407","author":"P Carmeliet","year":"2000","unstructured":"Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407(6801):249\u201357.","journal-title":"Nature"},{"issue":"14","key":"1357_CR33","first-page":"5587","volume":"61","author":"C Isogai","year":"2001","unstructured":"Isogai C, et al. Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin. Cancer Res. 2001;61(14):5587\u201394.","journal-title":"Cancer Res"},{"issue":"4","key":"1357_CR34","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ccr.2008.08.012","volume":"14","author":"K Bajou","year":"2008","unstructured":"Bajou K, et al. Plasminogen activator inhibitor-1 protects endothelial cells from FasL-mediated apoptosis. Cancer Cell. 2008;14(4):324\u201334.","journal-title":"Cancer Cell"},{"issue":"10","key":"1357_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24108877","volume":"24","author":"BT Shaker","year":"2023","unstructured":"Shaker BT, et al. The 14-kilodalton human growth hormone fragment a potent inhibitor of angiogenesis and tumor metastasis. Int J Mol Sci. 2023;24(10):8877.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1357_CR36","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/j.1755-148X.2009.00603.x","volume":"22","author":"D Chen","year":"2009","unstructured":"Chen D, et al. Ski knockdown inhibits human melanoma tumor growth in vivo. Pigment Cell Melanoma Res. 2009;22(6):761\u201372.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"1","key":"1357_CR37","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/exd.14681","volume":"32","author":"K Ohuchi","year":"2023","unstructured":"Ohuchi K, et al. Plasminogen activating inhibitor-1 promotes angiogenesis in cutaneous angiosarcomas. Exp Dermatol. 2023;32(1):50\u20139.","journal-title":"Exp Dermatol"},{"issue":"3","key":"1357_CR38","first-page":"636","volume":"60","author":"JA Foekens","year":"2000","unstructured":"Foekens JA, et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res. 2000;60(3):636\u201343.","journal-title":"Cancer Res"},{"key":"1357_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00071","volume":"8","author":"SP Bagaria","year":"2018","unstructured":"Bagaria SP, et al. Association between programmed death-ligand 1 expression and the vascular endothelial growth factor pathway in angiosarcoma. Front Oncol. 2018;8:71.","journal-title":"Front Oncol"},{"issue":"4","key":"1357_CR40","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1016\/j.bbrc.2016.12.048","volume":"482","author":"W Nie","year":"2017","unstructured":"Nie W, et al. Tumor-promoting effect of IL-23 in mammary cancer mediated by infiltration of M2 macrophages and neutrophils in tumor microenvironment. Biochem Biophys Res Commun. 2017;482(4):1400\u20136.","journal-title":"Biochem Biophys Res Commun"},{"issue":"12","key":"1357_CR41","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1016\/j.bbadis.2018.10.004","volume":"1864","author":"M Zang","year":"2018","unstructured":"Zang M, et al. IL-23 production of liver inflammatory macrophages to damaged hepatocytes promotes hepatocellular carcinoma development after chronic hepatitis B virus infection. Biochimica et Biophysica Acta (BBA). 2018;1864(12):3759\u201370.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"key":"1357_CR42","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jdcr.2021.09.035","volume":"17","author":"L Van Esbeen","year":"2021","unstructured":"Van Esbeen L, Roquet-Gravy PP. Improvement of Stewart-Treves angiosarcoma through interleukin 23p19 inhibition. JAAD Case Rep. 2021;17:84\u20136.","journal-title":"JAAD Case Rep"},{"issue":"1","key":"1357_CR43","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1159\/000506975","volume":"13","author":"S Yoshida","year":"2020","unstructured":"Yoshida S, et al. IL-23 expression in Stewart-Treves syndrome: two case reports and immunohistochemical investigation. Case Rep Oncol. 2020;13(1):462\u20137.","journal-title":"Case Rep Oncol"},{"issue":"19","key":"1357_CR44","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202400006R","volume":"38","author":"C Zhang","year":"2024","unstructured":"Zhang C, et al. IL-17A-neutralizing antibody ameliorates inflammation and fibrosis in rosacea by antagonizing the CXCL5\/CXCR2 axis. FASEB J. 2024;38(19):e70096.","journal-title":"FASEB J"},{"key":"1357_CR45","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-024-02167-3","author":"MM Gouda","year":"2024","unstructured":"Gouda MM, Chanderasekaran J, Balnadupete A, Bhandary YP, et al. Impact of curcumin on the IL-17A-mediated p53-fibrinolytic system: mouse proteomics and integrated human fibrosis scrnaseq insights. Inflammation. 2024. https:\/\/doi.org\/10.1007\/s10753-024-02167-3.","journal-title":"Inflammation"},{"issue":"10","key":"1357_CR46","doi-asserted-by":"publisher","first-page":"8015","DOI":"10.1007\/s11033-023-08671-3","volume":"50","author":"P Mao","year":"2023","unstructured":"Mao P, et al. CXCL5 promotes tumorigenesis and angiogenesis of glioblastoma via JAK-STAT\/NF-kappab signaling pathways. Mol Biol Rep. 2023;50(10):8015\u201323.","journal-title":"Mol Biol Rep"},{"issue":"4","key":"1357_CR47","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1172\/JCI115406","volume":"88","author":"AP Sappino","year":"1991","unstructured":"Sappino AP, et al. Differential protease expression by cutaneous squamous and basal cell carcinomas. J Clin Invest. 1991;88(4):1073\u20139.","journal-title":"J Clin Invest"},{"issue":"2","key":"1357_CR48","first-page":"85208","volume":"2007","author":"CE Wilkins-Port","year":"2007","unstructured":"Wilkins-Port CE, et al. PAI-1 is a critical upstream regulator of the TGF-beta1\/EGF-Induced invasive phenotype in mutant p53 human cutaneous squamous cell carcinoma. J Biomed Biotechnol. 2007;2007(2):85208.","journal-title":"J Biomed Biotechnol"},{"key":"1357_CR49","doi-asserted-by":"publisher","first-page":"963209","DOI":"10.1155\/2009\/963209","volume":"2009","author":"J Freytag","year":"2009","unstructured":"Freytag J, et al. PAI-1 regulates the invasive phenotype in human cutaneous squamous cell carcinoma. J Oncol. 2009;2009:963209.","journal-title":"J Oncol"},{"issue":"2","key":"1357_CR50","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/onc.2017.315","volume":"37","author":"A Mizrahi","year":"2018","unstructured":"Mizrahi A, et al. Alterations of microRNAs throughout the malignant evolution of cutaneous squamous cell carcinoma: the role of miR-497 in epithelial to mesenchymal transition of keratinocytes. Oncogene. 2018;37(2):218\u201330.","journal-title":"Oncogene"},{"key":"1357_CR51","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00403-017-1738-z","volume":"309","author":"KA Rubina","year":"2017","unstructured":"Rubina KA, et al. Increased expression of uPA, uPAR, and PAI-1 in psoriatic skin and in basal cell carcinomas. Arch Dermatol Res. 2017;309:433\u201342.","journal-title":"Arch Dermatol Res"},{"issue":"5","key":"1357_CR52","doi-asserted-by":"publisher","first-page":"522","DOI":"10.6004\/jnccn.2020.0022","volume":"18","author":"N Mehta-Shah","year":"2020","unstructured":"Mehta-Shah N, et al. NCCN guidelines insights: primary cutaneous lymphomas, version 2.2020. J Natl Compr Canc Netw. 2020;18(5):522\u201336.","journal-title":"J Natl Compr Canc Netw"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01357-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-025-01357-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01357-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T08:03:49Z","timestamp":1761293029000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-025-01357-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":52,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1357"],"URL":"https:\/\/doi.org\/10.1007\/s11864-025-01357-x","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"12 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}